137976-61-5

Basic information

• Product Name: 2-Methyl-N-[4-[(2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]phenyl]benzamide
• Synonyms: 2-Methyl-N-[4-[(2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]phenyl]benzamide
• CAS NO: 137976-61-5
• Molecular Formula: C₂₅H₂₂N₂O₃
• Molecular Weight: 398.45378
• Mol File: 137976-61-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 553.103 °C at 760 mmHg
• Flash Point: 288.307 °C
• Appearance: /
• Density: 1.27
• CAS DataBase Reference: 2-Methyl-N-[4-[(2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]phenyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-N-[4-[(2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]phenyl]benzamide(137976-61-5)
• EPA Substance Registry System: 2-Methyl-N-[4-[(2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]phenyl]benzamide(137976-61-5)

Safety Data

• Hazardous Substances Data: 137976-61-5(Hazardous Substances Data)

Usage

General Description

The chemical compound "2-Methyl-N-[4-[(2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]phenyl]benzamide" is a benzamide derivative with a molecular formula C27H26N2O3. It is a synthetic compound with potential pharmaceutical applications, specifically in the field of medicine. The compound contains a benzamide core structure with additional phenyl and tetrahydro-5-oxo-1H-1-benzazepin-1-yl groups. Its exact uses and functions are not specified, but its chemical structure suggests potential interactions with biological targets, making it a subject of interest for further research in drug development and medicinal chemistry.

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 137975-89-4 1-(4-nitrobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 1127-74-8 1,2,3,4-tetrahydro-5H-benzo[b] azepin-5-one 
• 933-88-0 ortho-toluoyl chloride 
• 137976-09-1 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro1H-1-benzazepin-5-one 
• 118-90-1 ortho-methylbenzoic acid 

Downstream Products

• 150681-95-1 (Methyl-{1-[4-(2-methyl-benzoylamino)-benzoyl]-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl}-amino)-acetic acid ethyl ester 
• 150681-17-7 N-[4-(5-Amino-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-2-methyl-benzamide 
• 222541-19-7 (E)-N-methyl-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetamide 
• 222541-18-6 ethyl <1-<4-(2-methylbenzoylamino)benzoyl>-2,3-dihydro-1H-1-benzoazepin-5-yl>acetate 
• 222541-29-9 ethyl <1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-yl>acetate 
• 222541-11-9 ethyl (E)-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetate 
• 154890-02-5 5-methylamino-1-[4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine 
• 150681-19-9 5-hydroxy-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine 

Relevant articles and documents

Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form

The anti and syn isomers of tolvaptan-type compounds, N-benzoyl-5-hydroxy-1-benzazepines (5a-c), were prepared in a stereocontrolled manner by biasing the conformation with a methyl group at C9 and C6, respectively, and the enantiomeric forms were separat

Condensed benzazepine derivative and pharmaceutical composition thereof

This invention relates to nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivatives represented by the general formula (I) STR1 (symbols in the formula have the following meanings; ring B: a nitrogen-containing aromatic 5-membered ring having at least 1 nitrogen atom and optionally one oxygen or sulfur atom, which may optionally have substituent(s), R1 and R2 : these may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, an amino group which may optionally be substituted by lower alkyl group(s), or a lower alkoxy group, A: a single bond; a group represented by the formula n: 0 or an integer of from 1 to 3, R3 and R4 : these may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group (provided that R3 and R4 may together form a lower alkylene group having 2 to 7 carbon atoms), and ring C: a benzene ring which may optionally have substituent(s)) and salts thereof; to pharmaceutical compositions which contain these compounds as an active ingredient and to intermediates which are useful in synthesizing these compounds. The compounds of this invention are useful as arginine vasopressin antagonists.